Inogen (NASDAQ:INGN) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Inogen (NASDAQ:INGN – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research note on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Read Our Latest Analysis on INGN

Inogen Price Performance

Shares of INGN opened at $5.63 on Friday. Inogen has a 52-week low of $5.05 and a 52-week high of $7.67. The business’s 50 day moving average price is $6.01 and its two-hundred day moving average price is $6.22.

Inogen (NASDAQ:INGN – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical technology company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The company had revenue of $77.19 million for the quarter, compared to analyst estimates of $92.25 million. Inogen had a negative return on equity of 19.29% and a negative net margin of 10.46%.

Institutional Trading of Inogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Goldman Sachs Group Inc. increased its holdings in shares of Inogen by 28.2% during the third quarter. Goldman Sachs Group Inc. now owns 558,309 shares of the medical technology company’s stock valued at $2,942,000 after acquiring an additional 122,724 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Inogen during the third quarter worth approximately $847,000. Empowered Funds LLC bought a new position in shares of Inogen in the 3rd quarter worth $190,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Inogen by 1.8% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 205,181 shares of the medical technology company’s stock worth $1,081,000 after purchasing an additional 3,650 shares in the last quarter. Finally, Royce & Associates LP bought a new position in shares of Inogen in the 3rd quarter worth $77,000. 89.94% of the stock is owned by institutional investors.

About Inogen

(Get Free Report)

Inogen, Inc. is a medical technology company focused on respiratory care. It develops, manufactures and markets oxygen concentrators and related products for people who require supplemental oxygen, including those with chronic respiratory conditions. Its products include the Inogen One line of portable oxygen concentrators, stationary oxygen concentrators and accessories. The company sells through direct-to-consumer channels and healthcare providers. Founded in 2001 and headquartered in Goleta, California, Inogen serves customers in the United States and international markets.

Further Reading

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.